Savara Inc.
SVRA
$0.09
Change (1 day)
$5.70
Year High
$2.82
Year Low
Categories
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
P/E ratio for Savara Inc. (SVRA)
P/E ratio as of 2023: -14.20
According to Savara Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -14.20. At the end of 2022 the company had a P/E ratio of -6.08.
P/E ratio history for Savara Inc. from 2000 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -14.20 |
| 2022 | -6.08 |
| 2021 | -3.67 |
| 2020 | -1.33 |
| 2019 | -1.71 |
| 2018 | -4.10 |
| 2017 | -8.73 |
| 2016 | -1.86 |
| 2015 | -1.71 |
| 2014 | -2.39 |
| 2013 | -1.65 |
| 2012 | -1.75 |
| 2011 | -1.25 |
| 2010 | -4.07 |
| 2009 | -3.60 |
| 2008 | -0.25 |
| 2007 | -1.83 |
| 2006 | -7.44 |
| 2005 | -7.92 |
| 2004 | -8.48 |
| 2003 | -29.33 |
| 2002 | -15.02 |
| 2001 | -1.80 |
| 2000 | -4.59 |